Chromadex logo

CDXC - Chromadex Share Price

$10.45 -0.3  -2.6%

Last Trade - 08/03/21

Sector
Healthcare
Size
Mid Cap
Market Cap £508.8m
Enterprise Value £497.7m
Revenue £41.1m
Position in Universe 3107th / 6647
Bullish
Bearish
Unlock CDXC Revenue
Momentum
Relative Strength (%)
1m +127.3%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -54.6%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
15.3 22.0 21.7 21.2 31.6 46.3 59.2 79.2 +24.8%
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the nine months ended 30 September 2020,Chromadex Corp revenues increased 32% to $43.8M. Net lossdecreased 41% to $13.8M. Revenues reflect an increase indemand for the Company's products and services due tofavorable market conditions. Lower net loss reflectsCorporate and other segment loss decrease of 73% to $6.5M,Consumer Products Segments income increase from $238K to$1.7M.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

CDXC Revenue Unlock CDXC Revenue

Net Income

CDXC Net Income Unlock CDXC Revenue

Normalised EPS

CDXC Normalised EPS Unlock CDXC Revenue

PE Ratio Range

CDXC PE Ratio Range Unlock CDXC Revenue

Dividend Yield Range

CDXC Dividend Yield Range Unlock CDXC Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
CDXC EPS Forecasts Unlock CDXC Revenue
Profile Summary

Chromadex Corporation is an integrated nutraceutical company. The Company and its subsidiaries ChromaDex, Inc., ChromaDex Analytics, Inc. and Spherix Consulting, Inc. provides research and quality-control products and services to the natural products industry. The Company partners with universities and research institutions worldwide to discover, develop and create solutions to deliver the full potential of nicotinamide adenine dinucleotide (NAD) and its impact on human health. The Company’s operated segments are: Consumer Product, Ingredients, and Analytical Reference Standards and Service Segment. Its Consumer Product segment offers TRU NIAGEN to consumers worldwide. Its ingredients business segment develops and commercializes ingredients, including nicotinamide riboside (NR), for which its brand name is NIAGEN. It also develops pterostilbene, which is marketed and sold under its brand name, pTeroPure.

Directors
Last Annual December 31st, 2019
Last Interim September 30th, 2020
Incorporated June 19, 2008
Public Since November 17, 2008
No. of Shareholders: 51
No. of Employees: 110
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Capital Market
Shares in Issue 65,633,881
Free Float (0.0%)
Eligible for
ISAs
SIPPs
CDXC Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for CDXC
Upcoming Events for CDXC
Frequently Asked Questions for Chromadex
What is the Chromadex share price?

As of 08/03/21, shares in Chromadex are trading at $10.45, giving the company a market capitalisation of £508.8m. This share price information is delayed by 15 minutes.

How has the Chromadex share price performed this year?

Shares in Chromadex are currently trading at $10.45 and the price has moved by 0.196k% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Chromadex price has moved by 0.134k% over the past year.

What are the analyst and broker recommendations for Chromadex?

Of the analysts with advisory recommendations for Chromadex, there are there are currently 2 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Chromadex is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Chromadex next release its financial results?

Chromadex is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-09-30
What is the Chromadex dividend yield?

Chromadex does not currently pay a dividend.

Does Chromadex pay a dividend?

Chromadex does not currently pay a dividend.

When does Chromadex next pay dividends?

Chromadex does not currently pay a dividend.

How do I buy Chromadex shares?

To buy shares in Chromadex you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Chromadex?

Shares in Chromadex are currently trading at $10.45, giving the company a market capitalisation of £508.8m.

Where are Chromadex shares listed? Where are Chromadex shares listed?

Here are the trading details for Chromadex:

Country of listing: United States
Exchange: NAQ
Ticker Symbol: CDXC
What kind of share is Chromadex?

Based on an overall assessment of its quality, value and momentum, Chromadex is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Chromadex share price forecast 2021?

Shares in Chromadex are currently priced at $10.45. At that level they are trading at 26.37% premium to the analyst consensus target price of 0.00.

Analysts covering Chromadex currently have a consensus Earnings Per Share (EPS) forecast of -0.318 for the next financial year.

How can I tell whether the Chromadex share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Chromadex. Over the past six months, the relative strength of its shares against the market has been 0.110k%. At the current price of $10.45, shares in Chromadex are trading at 0.105k% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Chromadex PE Ratio?

We were not able to find PE ratio data for Chromadex.

Who are the key directors of Chromadex?

Chromadex's management team is headed by:

Frank Jaksch - CHM
Stephen Block - IND
Jeffrey Baxter - IND
Robert Fried - CEO
Kurt Gustafson - LED
Steven Rubin - IND
Tony Lau - IND
Kevin Farr - CFO
Mark Friedman - GCN
Megan Jordan - SVP
Who are the major shareholders of Chromadex?

Here are the top five shareholders of Chromadex based on the size of their shareholding:

Champion River Ventures, Ltd. Corporation
Percentage owned: 9.9% (6.50m shares)
Pioneer Step Holdings, Ltd. Corporation
Percentage owned: 9.08% (5.96m shares)
Yong Rong (HK) Asset Management Limited Investment Advisor
Percentage owned: 5.86% (3.85m shares)
Winsave Resources, Ltd. Corporation
Percentage owned: 4.71% (3.09m shares)
BlackRock Institutional Trust Company, N.A. Investment Advisor
Percentage owned: 4.01% (2.63m shares)
Similar to CDXC
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.